drugset
drugset / Trial / NCT06030648

MT2022-01: MSCs for ALD

NCT06030648 ↗

Phase 1 Suspended 10 enrolled Masonic Cancer Center, University of Minnesota
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This is a single-institution study to evaluate the use of intravenously administered allogeneic, 3rd party mesenchymal stem cells (IV-MSC) in patients with active, cerebral adrenoleukodystrophy (CALD), as a bridge to hematopoietic stem cell transplant or gene therapy, or in patients who are too advanced for gene therapy or HSCT. The intervention will occur in the time between diagnosis of active CALD and transplant which is currently 8-12 weeks.

Timeline

Start
2023-08-28
Primary completion
2027-05-01
Completion
2029-05-01

Drugs

EvaluationDrugModalityDoseRoute
Subject mesenchymal stem cells Cell therapy 1e+06 cells/kg Intravenous

Indications

adrenoleukodystrophy